EP3247417B1 - Lubricious urinary catheters having varying flexibility - Google Patents
Lubricious urinary catheters having varying flexibility Download PDFInfo
- Publication number
- EP3247417B1 EP3247417B1 EP16702644.2A EP16702644A EP3247417B1 EP 3247417 B1 EP3247417 B1 EP 3247417B1 EP 16702644 A EP16702644 A EP 16702644A EP 3247417 B1 EP3247417 B1 EP 3247417B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- catheter
- vol
- plasticizing agent
- propylene glycol
- section
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002485 urinary effect Effects 0.000 title claims description 21
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 189
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 56
- 239000003795 chemical substances by application Substances 0.000 claims description 46
- 239000004372 Polyvinyl alcohol Substances 0.000 claims description 43
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 43
- 238000003780 insertion Methods 0.000 claims description 11
- 230000037431 insertion Effects 0.000 claims description 11
- 239000002904 solvent Substances 0.000 claims description 10
- 210000002700 urine Anatomy 0.000 claims description 4
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 claims 1
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 claims 1
- 239000000203 mixture Substances 0.000 description 17
- 239000007788 liquid Substances 0.000 description 14
- 239000000314 lubricant Substances 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 238000007654 immersion Methods 0.000 description 8
- 238000000576 coating method Methods 0.000 description 7
- 239000011248 coating agent Substances 0.000 description 6
- 238000000034 method Methods 0.000 description 5
- 210000003708 urethra Anatomy 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 4
- 239000002195 soluble material Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000001746 injection moulding Methods 0.000 description 3
- 238000002791 soaking Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000001125 extrusion Methods 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 229920002725 thermoplastic elastomer Polymers 0.000 description 2
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000000887 hydrating effect Effects 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000005660 hydrophilic surface Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 239000004814 polyurethane Substances 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/04—Macromolecular materials
- A61L29/041—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L29/00—Materials for catheters, medical tubing, cannulae, or endoscopes or for coating catheters
- A61L29/14—Materials characterised by their function or physical properties, e.g. lubricating compositions
- A61L29/141—Plasticizers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0043—Catheters; Hollow probes characterised by structural features
- A61M25/0054—Catheters; Hollow probes characterised by structural features with regions for increasing flexibility
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M27/00—Drainage appliance for wounds or the like, i.e. wound drains, implanted drains
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2210/00—Anatomical parts of the body
- A61M2210/10—Trunk
- A61M2210/1078—Urinary tract
- A61M2210/1089—Urethra
- A61M2210/1096—Male
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M25/00—Catheters; Hollow probes
- A61M25/0017—Catheters; Hollow probes specially adapted for long-term hygiene care, e.g. urethral or indwelling catheters to prevent infections
Definitions
- the present disclosure generally relates to urinary catheters. More particularly, the present disclosure relates to lubricous urinary catheters having a varying flexibility along their length and even more particularly to lubricious flushable catheters having varying flexibility.
- Catheters are used to treat many different types of medical conditions and typically include an elongated shaft that is inserted into and through a passageway or lumen of the body.
- Catheters, and in particular intermittent catheters are commonly used by those who suffer from various abnormalities of the urinary system, such as urinary incontinence. With the advent of intermittent catheters, individuals with urinary system abnormalities can self-insert and self-remove intermittent catheters several times a day.
- Catheters are commonly made from polymers, such as polyvinyl chloride (PVC), thermoplastic elastomers (TPE) and polyurethane (PU). It is common to lubricate such catheters so as to reduce friction to allow for easier and less traumatic insertion and withdrawal of the catheter.
- PVC polyvinyl chloride
- TPE thermoplastic elastomers
- PU polyurethane
- Gel lubricated catheters are made easier to insert and withdraw by application of a water-based lubricant on the outer surface of the catheter.
- a catheter can be supplied with lubricant which is applied on the outer surface just before or during the packaging operation.
- a user can apply lubricant to the catheter surface just prior to the catheter being inserted into the urethra.
- the handling of gel lubricated catheters by the user can be messy, leaving lubricant on the user's hands. Further, it can increase the risk of infection from microorganisms being introduced into the body through handling of the gel lubricated catheter.
- a hydrophilic coated catheter the catheter is provided with a thin hydrophilic coating which is applied to the outer surface of the catheter during its manufacture.
- the coating is activated by swelling the hydrophilic coating with a hydrating agent such as liquid water, water vapor, combinations thereof and the like to provide an extremely low coefficient of friction surface.
- a hydrating agent such as liquid water, water vapor, combinations thereof and the like to provide an extremely low coefficient of friction surface.
- the most common form of this product is one in which a sterile, individually packaged, single use catheter is provided in a dry state or condition. The user opens the package, pours water into the package, waits a predetermined period of time, for example, 30 seconds, and then removes the catheter from the package which is ready for insertion.
- Some hydrophilic coated catheters are provided in a package that contains enough liquid water to cause it to be immersed. Others are provided with a separate packet of water within the package wherein the packet contains a sufficient amount of water necessary to immerse the catheter within the package. In
- hydrophilic coated catheters which are wetted through immersion in a liquid
- the liquid has a tendency to spill from the package as the user handles the catheter and tries to remove it from the package for subsequent insertion.
- special packaging requirements increase the complexity of such catheter systems.
- Another disadvantage of the hydrophilic coated catheter is that the catheter has an extremely slippery surface which makes it quite difficult for the user to handle during insertion.
- Flushable catheters may be made from water soluble polymers or polymers that disintegrate, degrade or break up in water. Gel lubricants and hydrophilic coatings may not be suitable for use with catheters made of such water soluble materials due to the material's sensitivity to water.
- medical catheters typically include a shaft that is sufficiently flexible to navigate the curves of a body lumen (especially urinary catheters intended for male users), yet rigid enough to be pushed through the urethra without collapsing or buckling before an end of the catheter reaches the bladder
- WO2007/028058 A2 discloses a catheter including an elongate shaft which can include an inner and outer layer with a swellable coating between. The coating can be swelled with water.
- the present disclosure provides urinary catheters with one or more of improved flexibility/rigidity, lubricity and/or flushable characteristics.
- a urinary catheter comprising: a catheter shaft having a proximal insertion end portion including a drainage opening for draining urine from the bladder and a distal end portion having a drainage member associated therewith, the catheter shaft being made of polyvinyl alcohol, the shaft including a first section having a first stiffness and a second section having a second stiffness, wherein at least one of said section is impregnated with a plasticizing agent including propylene glycol.
- a method of making a catheter of varying stiffness includes immersing a first section of a catheter made from polyvinyl alcohol in a first plasticizing agent and immersing a second section of the catheter made in a second plasticizing agent.
- the present disclosure is directed to medical devices that include shafts or tubes that may be inserted into and advanced within a lumen of a body, such as a urethra.
- Such medical devices include urinary catheters.
- the medical devices of the present disclosure include tubes that are made from a water soluble material(s) which may be placed into the sewer system for disposal thereof, e.g. flushed down a toilet. When placed in the sewer system, the water soluble materials of the tubes are dissolved or broken up by the water within the sewer system.
- the stiffness of the tubes disclosed herein may vary along the length of the tube which may assist in navigation of the tube through curves and restrictions of a body lumen. Furthermore, the tubes may also be lubricous so as to ease advance and withdrawal of the tube into and from the body lumen.
- the urinary catheter of the present invention includes a catheter shaft that has a proximal insertion end portion and a distal end portion.
- the proximal insertion end portion of catheter shaft includes eyelets or drainage openings for draining urine from the bladder.
- the distal end portion of the catheter shaft has a drainage member, such as a funnel, associated therewith.
- the drainage member may be integral with the catheter shaft or may be attached to the catheter shaft.
- the catheter shaft is a tube that has a lumen extending therethrough for the passage of urine from the eyelets to the drainage member.
- the catheter shaft is made from polyvinyl alcohol (PVOH), which may be a warm or cold water soluble PVOH or a mixture thereof.
- PVOH polyvinyl alcohol
- the catheter shaft may also be made from a mixture of PVOH with other polymers or additives.
- the catheter shaft and the materials thereof i.e., PVOH with or without other polymers or additives
- the drainage portion of the catheter may also be made of flushable material, such as a water soluble material and for example PVOH.
- the PVOH of the catheter shaft is impregnated with a plasticizing agent that causes plasticization of the PVOH to reduce the stiffness/increase the flexibility of the PVOH catheter shaft.
- the plasticizing agent is a non-solvent of PVOH, such as propylene glycol.
- the plasticizing agent is a mixture of a non-solvent of PVOH and a PVOH solvent such as a mixture of propylene glycol and water. Such mixture may include between about 99% - about 60% propylene glycol by volume (vol%) and about 1 vol% - about 40 vol% of water.
- the mixture may include 90 vol% propylene glycol and 10 vol% water; 80 vol% propylene glycol and 20 vol% water; 70 vol% propylene glycol and 30 vol% water; or 60 vol% propylene glycol and 40 vol% water.
- the catheter shafts may be impregnated with the plasticizing agent by soaking the catheter shafts or portions thereof in the plasticizing agent for a selected time period.
- the amount of plasticizing agent impregnated within the catheter shaft and/or the amount of plasticization that occurs can depend on several factors including but not limited to the length of soaking time and/or the concentration of the components within the plasticizing agent.
- the selected soaking time could be from a few minutes to several hours depending on the desired results, temperature and degree of hydrolysis of the polyvinyl alcohol material.
- the entire catheter is impregnated with a plasticizing agent by immersing the entire catheter shaft within the plasticizing agent.
- different sections of the catheter shaft may be impregnated with different plasticizing agents or impregnated with different amounts/concentrations of the same plasticizing agent.
- a first section of the catheter may be immersed within a first plasticizing agent for a selected time period and another portion may be immersed in a second, different plasticizing agent for a selected period of time.
- a first section of the catheter may be immersed within a plasticizing agent for a first period of time and a second section of the catheter shaft may be immersed in the same plasticizing agent for a second period of time that is different from the first period of time.
- one section of the catheter may be impregnated with a plasticizing agent while another section is not impregnated with any plasticizing agent.
- the impregnated catheter shafts may weigh between about 10% and about 100% of the original weight of the catheter shaft. Preferably, the catheter shafts weigh between 5% and 40% of the original weight of the catheter shafts.
- the proximal insertion end of a catheter may be impregnated with a plasticizing agent to cause plasticization of the material of the proximal insertion end of the catheter so that the proximal insertion end is more flexible than a portion of the catheter shaft distal of the proximal end portion.
- This distal portion which is relatively stiffer than the proximal end portion, may or may not be impregnated with a plasticizing agent. If impregnated with a plasticizing agent, this distal portion may be impregnated with a different plasticizing agent or a different amount of plasticizing agent.
- the distal end portion may be impregnated with a plasticizing agent so that the distal end portion is more flexible than a portion of the catheter shaft proximal the distal end portion.
- This proximal portion which is relatively stiffer than the distal end portion, may or may not be impregnated with a plasticizing agent. The difference in stiffness between the proximal and distal end portions may make it easier to navigate the catheter shaft through the curves and restrictions of the urethra, e.g., past the prostate.
- the plasticizing agent may also function as a lubricant that causes or provides lubricity to the outer surface of the catheter.
- a lubricant that causes or provides lubricity to the outer surface of the catheter.
- catheter shafts soaked in propylene glycol or mixtures of propylene glycol and water have a lubricous outer surface that eases advancement of the catheter shaft through the urethra without the need for additional lubricant.
- additional lubricant may be used if desired.
- the catheter may be lubricated in some other manner, such as with a gel or hydrophilic coating.
- the catheter shaft is made of a water soluble PVOH that may be disposed of by flushing down the toilet, such as Mowiflex TC 251 or Mowiflex TC 232 supplied by Kuraray.
- the PVOH may be formed into the catheter shaft by any suitable process such as by extrusion, injection molding or by the exjection process set forth in WO2014/052770 .
- the PVOH catheter shaft or sections thereof may be impregnated with one or more plasticizing agents to reduce the stiffness/increase the flexibility of the catheter or sections thereof.
- a first section of the PVOH catheter shaft may be immersed in a plasticizing agent including a mixture of propylene glycol and water wherein the propylene glycol is 90 vol% and the water is 10 vol% of the mixture.
- This first section of the shaft may be immersed in the plasticizing agent for up to about 24 hours, wherein the immersed shaft is impregnated with the plasticizing agent and gains about 10% of its original weight.
- a second section of the shaft may be immersed in a plasticizing agent including a mixture of propylene glycol and water wherein the propylene glycol is 80 vol% and the water is 20 vol% of the mixture.
- This second section of the shaft may be immersed in this plasticizing agent for up to about 24 hours, wherein the immersed shaft is impregnated with the plasticizing agent and gains about 30% of its original weight.
- the first and second sections may be immersed in the respective plasticizing agent for more than 24 hours, if desired.
- the first section of the catheter tube has a relatively greater stiffness than the second section.
- the catheter shaft may have a coefficient of friction of about 0.2 or less.
- the propylene glycol may be compounded with the PVOH prior to forming compounded material into a catheter, by for example, injection molding or extrusion.
- PVOH may be compounded with propylene glycol in a twin extruder to form the compounded material.
- the propylene glycol is between about 10 wt% to about 40wt% of the compounded material.
- the propylene glycol may be about 30 wt% of the compound. The compounded material thus formed may then be formed into a catheter or other medical device.
- PVOH catheter tubes were made from PVOH supplied by Kuraray and sold under trade name Mowiflex TC232. The tubes were produced by the exjection process disclosed in WO2014/052770 .
- a first half of the tube was immersed at room temperature (substantially 23oC) for 1 day (about 24 hours) in a mixture of propylene glycol (PG) and water wherein the mixture was 90 vol% PG and 10 vol% water.
- the immersed tube absorbed liquid and gained approximately 10% in weight.
- the second half of the tube was immersed at room temperature (substantially 23oC) for 1 day (about 24 hours) in a mixture of PG 80 vol% and water 20 vol%.
- the immersed tube again absorbed liquid and gained.
- the resulting tube had two distinct portions of differing stiffness wherein the first half of the tube (immersed in PG/ water at 90 vol%/10 vol%) was more rigid than the second half of the tube.
- Example 2 the above-discussed exjection processes was used to make PVOH tubes for two different types of PVOH.
- the first set of tubes was made from PVOH sold under the trade name Mowiflex TC 232, supplied by Kuraray.
- the second of tubes was made from PVOH sold under the trade name Mowiflex TC 251, also supplied by Kuraray.
- Tubes from each of the different sets were placed in one of: (1) 100% propylene glycol, (2) a mixture of 90 vol% propylene glycol and 10 vol% water, (3) a mixture of 80 vol% propylene glycol and 20 vol% water or (4) a mixture of 70 vol% propylene glycol and 30 vol% water.
- the PVOH tubes were placed in the respective liquid(s) for a period of seven days.
- the tubes were weighed on days 0, 1, 2, 3, 6 and 7 to measure the amount of liquid uptake that occurred during that time period. Below are the results from this Example.
- PVOH plaques were made from PVOH supplied by Kuraray and sold under trade name Mowiflex TC232. PVOH was compounded with propylene glycol using a Rondol 21 mm twin screw extruder with a 40 L/D. PVOH chips were fed through a gravimetric feeder into the extruder at the standard feed throat (zone 0). Propylene glycol was fed into the extruder with a calibrated pump through zone 1. The compound was extruded onto a moving belt and cooled by air. The compound has about 30 wt% propylene glycol. The solidified extruded strands were fed into a standard pelletizer.
- One set of injection molded plaques were produced form the compounded PVOH chips having 30 wt% propylene glycol.
- a second set of plaques was produced from only PVOH, i.e., having no propylene glycol.
- An Engle VC200-50 injection molding machine with a screw diameter of 25 mm was utilized. The melt was injected at 200° C into a rectangular mold at 40° C, producing plaques rectangular plaques 13 cm long, 2.5 cm wide and 0.2 cm thick.
- a first sample of plaques made from only PVOH were immersed in a solution of 80% in volume of propylene glycol and 20 vol% water for 8 hours at room temperature. The samples were removed from the solution and the excess liquid removed from the surface with a tissue prior to dynamic mechanical analysis testing (DMA).
- DMA dynamic mechanical analysis testing
- a second sample of plaques made from only PVOH were immersed in 100% propylene glycol at room temperature for several days. Samples were removed from the propylene glycol and the excess liquid removed from the surface with a tissue prior to DMA testing.
- the storage (shear) modulus of plasticized and un-plasticized plaques was measured by DMA using a Q800 TA Instrument Dynamic Mechanical Analyzer.
- the cantilever test mode at a frequency of 1Hz, amplitude of 40 micrometers and a distance of 17mm between the support jaws was used.
- the dynamic mechanical load was applied at the middle point between the jaws and onto a specimen having dimensions 2mm thick, 6mm wide and 33mm long, cut from the injection molded plaques.
- the percent of gained weight was measured after immersion of the PVOH plaques in 100% PG and a solution of 80/20 PG/water. The excess liquid removed from the surface with a tissue prior to measuring the weight.
- Table 3 shows the summary of the results of shear storage modulus (G') and percent of PG uptake at room temperature for plaques immersed in 100% PG for up to 27 days. As can be seen the storage modulus decreases very rapidly after 4 days immersion at levels of after 20 days, with very little change thereafter.
- Table 3 Shear storage modulus (G') at 25° C and percent of propylene glycol uptake relative to the weight of the dry PVOH plaques immersed in 100% propylene glycol as a function of immersion time. Immersion time [days] G' [MPa] PG uptake [%] 0 (dry) 3811 0 4 454 13.4 16 136 25 17 95 29 20 51 30 27 52 34
- Table 4 shows the summary of the results of shear storage modulus (G') and percent propylene glycol /water uptake at room temperature for plaques immersed in a solution 80/20 propylene glycol /water for up to 12 hours. As can be seen the storage shear modulus decreases very rapidly after 6 hours immersion and reaches a value of 56 MPa and 38% uptake after 12 hours.
- Table 4 Shear storage modulus (G') at 25° C and percent of propylene glycol /water uptake relative to the weight of the dry PVOH plaques immersed in 80/20 propylene glycol /water as a function of immersion time Immersion time [hours] G' [MPa] PG/water uptake [%] 0 3811 0 6 245 28 12 56 38
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Anesthesiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Biophysics (AREA)
- Otolaryngology (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Chemistry (AREA)
- Polymers & Plastics (AREA)
- Organic Chemistry (AREA)
Description
- The present disclosure generally relates to urinary catheters. More particularly, the present disclosure relates to lubricous urinary catheters having a varying flexibility along their length and even more particularly to lubricious flushable catheters having varying flexibility.
- Catheters are used to treat many different types of medical conditions and typically include an elongated shaft that is inserted into and through a passageway or lumen of the body. Catheters, and in particular intermittent catheters, are commonly used by those who suffer from various abnormalities of the urinary system, such as urinary incontinence. With the advent of intermittent catheters, individuals with urinary system abnormalities can self-insert and self-remove intermittent catheters several times a day.
- Catheters are commonly made from polymers, such as polyvinyl chloride (PVC), thermoplastic elastomers (TPE) and polyurethane (PU). It is common to lubricate such catheters so as to reduce friction to allow for easier and less traumatic insertion and withdrawal of the catheter. Currently, there are two main categories of lubricated catheters, namely gel lubricated catheters and hydrophilic coated catheters.
- Gel lubricated catheters are made easier to insert and withdraw by application of a water-based lubricant on the outer surface of the catheter. A catheter can be supplied with lubricant which is applied on the outer surface just before or during the packaging operation. Alternatively, a user can apply lubricant to the catheter surface just prior to the catheter being inserted into the urethra. However, the handling of gel lubricated catheters by the user can be messy, leaving lubricant on the user's hands. Further, it can increase the risk of infection from microorganisms being introduced into the body through handling of the gel lubricated catheter.
- In a hydrophilic coated catheter, the catheter is provided with a thin hydrophilic coating which is applied to the outer surface of the catheter during its manufacture. The coating is activated by swelling the hydrophilic coating with a hydrating agent such as liquid water, water vapor, combinations thereof and the like to provide an extremely low coefficient of friction surface. The most common form of this product is one in which a sterile, individually packaged, single use catheter is provided in a dry state or condition. The user opens the package, pours water into the package, waits a predetermined period of time, for example, 30 seconds, and then removes the catheter from the package which is ready for insertion. Some hydrophilic coated catheters are provided in a package that contains enough liquid water to cause it to be immersed. Others are provided with a separate packet of water within the package wherein the packet contains a sufficient amount of water necessary to immerse the catheter within the package. In this type of package, the packet is burst open within the package just prior to use.
- One disadvantage of the hydrophilic coated catheters which are wetted through immersion in a liquid is that the liquid has a tendency to spill from the package as the user handles the catheter and tries to remove it from the package for subsequent insertion. Further, special packaging requirements increase the complexity of such catheter systems. Another disadvantage of the hydrophilic coated catheter is that the catheter has an extremely slippery surface which makes it quite difficult for the user to handle during insertion.
- Interest has been increasing in flushable catheters, which may be disposed of by flushing down the toilet. Flushable catheters may be made from water soluble polymers or polymers that disintegrate, degrade or break up in water. Gel lubricants and hydrophilic coatings may not be suitable for use with catheters made of such water soluble materials due to the material's sensitivity to water.
- Additionally, medical catheters typically include a shaft that is sufficiently flexible to navigate the curves of a body lumen (especially urinary catheters intended for male users), yet rigid enough to be pushed through the urethra without collapsing or buckling before an end of the catheter reaches the bladder
WO2007/028058 A2 discloses a catheter including an elongate shaft which can include an inner and outer layer with a swellable coating between. The coating can be swelled with water. - Therefore, there is a need for improved catheters having a lubricious surface without the user having to handle gel-lubricants and without the risk of water spillage while opening the package or activating the hydrophilic surface and for the catheter to have sufficient flexibility to navigate the curves of a body lumen.
- The present disclosure provides urinary catheters with one or more of improved flexibility/rigidity, lubricity and/or flushable characteristics.
- The invention is defined by the claims. Any subject-matter falling outside the scope of the claims is provided for information purposes only. The present invention discloses a urinary catheter comprising: a catheter shaft having a proximal insertion end portion including a drainage opening for draining urine from the bladder and a distal end portion having a drainage member associated therewith, the catheter shaft being made of polyvinyl alcohol, the shaft including a first section having a first stiffness and a second section having a second stiffness, wherein at least one of said section is impregnated with a plasticizing agent including propylene glycol.
- In another aspect, a method of making a catheter of varying stiffness is provided. The method includes immersing a first section of a catheter made from polyvinyl alcohol in a first plasticizing agent and immersing a second section of the catheter made in a second plasticizing agent.
- The present disclosure is directed to medical devices that include shafts or tubes that may be inserted into and advanced within a lumen of a body, such as a urethra. Such medical devices include urinary catheters.
- The medical devices of the present disclosure include tubes that are made from a water soluble material(s) which may be placed into the sewer system for disposal thereof, e.g. flushed down a toilet. When placed in the sewer system, the water soluble materials of the tubes are dissolved or broken up by the water within the sewer system.
- The stiffness of the tubes disclosed herein may vary along the length of the tube which may assist in navigation of the tube through curves and restrictions of a body lumen. Furthermore, the tubes may also be lubricous so as to ease advance and withdrawal of the tube into and from the body lumen.
- The urinary catheter of the present invention includes a catheter shaft that has a proximal insertion end portion and a distal end portion. The proximal insertion end portion of catheter shaft includes eyelets or drainage openings for draining urine from the bladder. The distal end portion of the catheter shaft has a drainage member, such as a funnel, associated therewith. The drainage member may be integral with the catheter shaft or may be attached to the catheter shaft. The catheter shaft is a tube that has a lumen extending therethrough for the passage of urine from the eyelets to the drainage member.
- The catheter shaft is made from polyvinyl alcohol (PVOH), which may be a warm or cold water soluble PVOH or a mixture thereof. The catheter shaft may also be made from a mixture of PVOH with other polymers or additives. The catheter shaft and the materials thereof (i.e., PVOH with or without other polymers or additives) are preferably suitable for being flushed down the toilet for disposal of the catheter. Furthermore, the drainage portion of the catheter may also be made of flushable material, such as a water soluble material and for example PVOH.
- The PVOH of the catheter shaft is impregnated with a plasticizing agent that causes plasticization of the PVOH to reduce the stiffness/increase the flexibility of the PVOH catheter shaft. The plasticizing agent is a non-solvent of PVOH, such as propylene glycol. In another embodiment, the plasticizing agent is a mixture of a non-solvent of PVOH and a PVOH solvent such as a mixture of propylene glycol and water. Such mixture may include between about 99% - about 60% propylene glycol by volume (vol%) and about 1 vol% - about 40 vol% of water. For example, the mixture may include 90 vol% propylene glycol and 10 vol% water; 80 vol% propylene glycol and 20 vol% water; 70 vol% propylene glycol and 30 vol% water; or 60 vol% propylene glycol and 40 vol% water.
- The catheter shafts may be impregnated with the plasticizing agent by soaking the catheter shafts or portions thereof in the plasticizing agent for a selected time period. The amount of plasticizing agent impregnated within the catheter shaft and/or the amount of plasticization that occurs can depend on several factors including but not limited to the length of soaking time and/or the concentration of the components within the plasticizing agent. The selected soaking time could be from a few minutes to several hours depending on the desired results, temperature and degree of hydrolysis of the polyvinyl alcohol material. In one embodiment, the entire catheter is impregnated with a plasticizing agent by immersing the entire catheter shaft within the plasticizing agent. In other embodiments, different sections of the catheter shaft may be impregnated with different plasticizing agents or impregnated with different amounts/concentrations of the same plasticizing agent. For example, a first section of the catheter may be immersed within a first plasticizing agent for a selected time period and another portion may be immersed in a second, different plasticizing agent for a selected period of time. In yet another embodiment, a first section of the catheter may be immersed within a plasticizing agent for a first period of time and a second section of the catheter shaft may be immersed in the same plasticizing agent for a second period of time that is different from the first period of time. In yet another embodiment, one section of the catheter may be impregnated with a plasticizing agent while another section is not impregnated with any plasticizing agent.
- The impregnated catheter shafts may weigh between about 10% and about 100% of the original weight of the catheter shaft. Preferably, the catheter shafts weigh between 5% and 40% of the original weight of the catheter shafts.
- In one particular example, the proximal insertion end of a catheter may be impregnated with a plasticizing agent to cause plasticization of the material of the proximal insertion end of the catheter so that the proximal insertion end is more flexible than a portion of the catheter shaft distal of the proximal end portion. This distal portion, which is relatively stiffer than the proximal end portion, may or may not be impregnated with a plasticizing agent. If impregnated with a plasticizing agent, this distal portion may be impregnated with a different plasticizing agent or a different amount of plasticizing agent. In another embodiment, the distal end portion may be impregnated with a plasticizing agent so that the distal end portion is more flexible than a portion of the catheter shaft proximal the distal end portion. This proximal portion, which is relatively stiffer than the distal end portion, may or may not be impregnated with a plasticizing agent. The difference in stiffness between the proximal and distal end portions may make it easier to navigate the catheter shaft through the curves and restrictions of the urethra, e.g., past the prostate.
- In some embodiments, the plasticizing agent may also function as a lubricant that causes or provides lubricity to the outer surface of the catheter. For example, catheter shafts soaked in propylene glycol or mixtures of propylene glycol and water have a lubricous outer surface that eases advancement of the catheter shaft through the urethra without the need for additional lubricant. However, additional lubricant may be used if desired. In other embodiments, the catheter may be lubricated in some other manner, such as with a gel or hydrophilic coating.
- In one embodiment, the catheter shaft is made of a water soluble PVOH that may be disposed of by flushing down the toilet, such as Mowiflex TC 251 or Mowiflex TC 232 supplied by Kuraray. The PVOH may be formed into the catheter shaft by any suitable process such as by extrusion, injection molding or by the exjection process set forth in
WO2014/052770 . The PVOH catheter shaft or sections thereof may be impregnated with one or more plasticizing agents to reduce the stiffness/increase the flexibility of the catheter or sections thereof. For example, a first section of the PVOH catheter shaft may be immersed in a plasticizing agent including a mixture of propylene glycol and water wherein the propylene glycol is 90 vol% and the water is 10 vol% of the mixture. This first section of the shaft may be immersed in the plasticizing agent for up to about 24 hours, wherein the immersed shaft is impregnated with the plasticizing agent and gains about 10% of its original weight. A second section of the shaft may be immersed in a plasticizing agent including a mixture of propylene glycol and water wherein the propylene glycol is 80 vol% and the water is 20 vol% of the mixture. This second section of the shaft may be immersed in this plasticizing agent for up to about 24 hours, wherein the immersed shaft is impregnated with the plasticizing agent and gains about 30% of its original weight. Depending on the desired result, the first and second sections may be immersed in the respective plasticizing agent for more than 24 hours, if desired. In this embodiment, the first section of the catheter tube has a relatively greater stiffness than the second section. Additionally, the catheter shaft may have a coefficient of friction of about 0.2 or less. - In another embodiment, the propylene glycol may be compounded with the PVOH prior to forming compounded material into a catheter, by for example, injection molding or extrusion. For instance, PVOH may be compounded with propylene glycol in a twin extruder to form the compounded material. In one embodiment, the propylene glycol is between about 10 wt% to about 40wt% of the compounded material. For example, the propylene glycol may be about 30 wt% of the compound. The compounded material thus formed may then be formed into a catheter or other medical device.
- PVOH catheter tubes were made from PVOH supplied by Kuraray and sold under trade name Mowiflex TC232. The tubes were produced by the exjection process disclosed in
WO2014/052770 . - A first half of the tube was immersed at room temperature (substantially 23ºC) for 1 day (about 24 hours) in a mixture of propylene glycol (PG) and water wherein the mixture was 90 vol% PG and 10 vol% water. The immersed tube absorbed liquid and gained approximately 10% in weight.
- The second half of the tube was immersed at room temperature (substantially 23ºC) for 1 day (about 24 hours) in a mixture of PG 80 vol% and water 20 vol%. The immersed tube again absorbed liquid and gained. The resulting tube had two distinct portions of differing stiffness wherein the first half of the tube (immersed in PG/ water at 90 vol%/10 vol%) was more rigid than the second half of the tube.
- In Example 2, the above-discussed exjection processes was used to make PVOH tubes for two different types of PVOH. The first set of tubes was made from PVOH sold under the trade name Mowiflex TC 232, supplied by Kuraray. The second of tubes was made from PVOH sold under the trade name Mowiflex TC 251, also supplied by Kuraray.
- Tubes from each of the different sets were placed in one of: (1) 100% propylene glycol, (2) a mixture of 90 vol% propylene glycol and 10 vol% water, (3) a mixture of 80 vol% propylene glycol and 20 vol% water or (4) a mixture of 70 vol% propylene glycol and 30 vol% water. The PVOH tubes were placed in the respective liquid(s) for a period of seven days. The tubes were weighed on days 0, 1, 2, 3, 6 and 7 to measure the amount of liquid uptake that occurred during that time period. Below are the results from this Example.
Table 1 Time Percent Mass Change of Mowiflex TC 232 [days] 100% PG/0% water 90%PG/10% water 80% PG/20% water 70% PG/30% water 0 0.0% 0.0% 0.0% 0.0% 1 4.0% 11.0% 27.5% 57.1% 2 5.4% 14.0% 35.6% 76.6% 3 6.5% 17.9% 48.7% 117.4% 6 8.7% 23.6% 77.7% 201.7% 7 9.5% 25.7% 91.2% 237.8% Table 2 Time Percent Mass Change of Mowiflex TC 251 [days] 100% PG/0% water 90%PG/10% water 80% PG/20% water 70% PG/30% water 0 0.0% 0.0% 0.0% 0.0% 1 2.5% 10.8% 33.5% 51.0% 2 3.1% 14.1% 44.9% 71.2% 3 4.1% 18.6% 62.7% 102.4% 6 5.8% 26.6% 95.8% 153.5% 7 6.4% 29.9% 107.7% 171.8% - The greater the gain in weight, the more plasticized the tube became. It was observed that the ratio of propylene glycol to water affected the rates or speeds of plasticization of the tubing. For example, a higher concentration of water resulted in more plasticization which results in a more flexible tube. Similarly, a longer soak time in the liquid also resulted in more plasticization and a more flexible tube. This is an indication that the mechanical properties of the tubing can be controlled from rigid to plastic to gel by varying the concentration of water and/or the length of dwell time in the liquid. After removal from liquid, the tubes retained their flexibility for several days.
- PVOH plaques were made from PVOH supplied by Kuraray and sold under trade name Mowiflex TC232. PVOH was compounded with propylene glycol using a Rondol 21 mm twin screw extruder with a 40 L/D. PVOH chips were fed through a gravimetric feeder into the extruder at the standard feed throat (zone 0). Propylene glycol was fed into the extruder with a calibrated pump through zone 1. The compound was extruded onto a moving belt and cooled by air. The compound has about 30 wt% propylene glycol. The solidified extruded strands were fed into a standard pelletizer.
- One set of injection molded plaques were produced form the compounded PVOH chips having 30 wt% propylene glycol. A second set of plaques was produced from only PVOH, i.e., having no propylene glycol. An Engle VC200-50 injection molding machine with a screw diameter of 25 mm was utilized. The melt was injected at 200° C into a rectangular mold at 40° C, producing plaques rectangular plaques 13 cm long, 2.5 cm wide and 0.2 cm thick.
- A first sample of plaques made from only PVOH were immersed in a solution of 80% in volume of propylene glycol and 20 vol% water for 8 hours at room temperature. The samples were removed from the solution and the excess liquid removed from the surface with a tissue prior to dynamic mechanical analysis testing (DMA).
- A second sample of plaques made from only PVOH were immersed in 100% propylene glycol at room temperature for several days. Samples were removed from the propylene glycol and the excess liquid removed from the surface with a tissue prior to DMA testing.
- The storage (shear) modulus of plasticized and un-plasticized plaques was measured by DMA using a Q800 TA Instrument Dynamic Mechanical Analyzer. The cantilever test mode at a frequency of 1Hz, amplitude of 40 micrometers and a distance of 17mm between the support jaws was used. The dynamic mechanical load was applied at the middle point between the jaws and onto a specimen having dimensions 2mm thick, 6mm wide and 33mm long, cut from the injection molded plaques.
- The percent of gained weight was measured after immersion of the PVOH plaques in 100% PG and a solution of 80/20 PG/water. The excess liquid removed from the surface with a tissue prior to measuring the weight.
- Table 3 shows the summary of the results of shear storage modulus (G') and percent of PG uptake at room temperature for plaques immersed in 100% PG for up to 27 days. As can be seen the storage modulus decreases very rapidly after 4 days immersion at levels of after 20 days, with very little change thereafter.
Table 3 Shear storage modulus (G') at 25° C and percent of propylene glycol uptake relative to the weight of the dry PVOH plaques immersed in 100% propylene glycol as a function of immersion time. Immersion time [days] G' [MPa] PG uptake [%] 0 (dry) 3811 0 4 454 13.4 16 136 25 17 95 29 20 51 30 27 52 34 - Table 4 shows the summary of the results of shear storage modulus (G') and percent propylene glycol /water uptake at room temperature for plaques immersed in a solution 80/20 propylene glycol /water for up to 12 hours. As can be seen the storage shear modulus decreases very rapidly after 6 hours immersion and reaches a value of 56 MPa and 38% uptake after 12 hours.
Table 4 Shear storage modulus (G') at 25° C and percent of propylene glycol /water uptake relative to the weight of the dry PVOH plaques immersed in 80/20 propylene glycol /water as a function of immersion time Immersion time [hours] G' [MPa] PG/water uptake [%] 0 3811 0 6 245 28 12 56 38 - Injection molded PVOH plaques with nominally 30% propylene glycol (propylene glycol and PVOH compounded using a twin screw extruder) showed a shear storage modulus at 25° C of G'=25 MPa.
Claims (11)
- A urinary catheter, comprising:
a catheter shaft having a proximal insertion end portion including a drainage opening for draining urine from the bladder and a distal end portion having a drainage member associated therewith, the catheter shaft being made of polyvinyl alcohol, the shaft including a first section having a first stiffness and a second section having a second stiffness, wherein at least one of said sections is impregnated with a plasticizing agent comprising propylene glycol. - The urinary catheter of claim 1, wherein the first section has greater stiffness than the second section.
- The urinary catheter of claim 1, wherein the second section has a greater stiffness than the first section.
- The urinary catheter of any one of claims 1-3, wherein the first section is impregnated with the plasticizing agent.
- The urinary catheter of any one of claims 1-4, wherein the second section is impregnated with the plasticizing agent.
- The urinary catheter of any one of claims 1-5, wherein the plasticizing agent lubricates the catheter.
- The urinary catheter of any one of claims 1-6, wherein the plasticizing agent further comprises a solvent for polyvinyl alcohol.
- The urinary catheter of claim 7, wherein the plasticizing agent comprises water.
- The urinary catheter of claim 7, wherein the ratio of the solvent to propylene glycol is one of 100 vol% propylene glycol and 0 vol% solvent; 90 vol% propylene glycol and 10 vol% solvent; 80 vol% propylene glycol and 20 vol% solvent; and 70 vol% propylene gycol and 30 vol% solvent.
- The urinary catheter of claim 9, wherein the solvent comprises water.
- The urinary catheter of any one of claims 1-3, 6-8 and 9-10, wherein the first section of the shaft has an amount of plasticizing agent impregnated therein, and the second section of the shaft has a second amount of plasticizing agent impregnated therein, wherein the second amount of plasticizing agent is different from the first amount.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562106446P | 2015-01-22 | 2015-01-22 | |
US201562232919P | 2015-09-25 | 2015-09-25 | |
PCT/US2016/014034 WO2016118569A1 (en) | 2015-01-22 | 2016-01-20 | Lubricious urinary catheters having varying flexibility |
Publications (2)
Publication Number | Publication Date |
---|---|
EP3247417A1 EP3247417A1 (en) | 2017-11-29 |
EP3247417B1 true EP3247417B1 (en) | 2021-03-10 |
Family
ID=55275222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP16702644.2A Active EP3247417B1 (en) | 2015-01-22 | 2016-01-20 | Lubricious urinary catheters having varying flexibility |
Country Status (9)
Country | Link |
---|---|
US (1) | US10946120B2 (en) |
EP (1) | EP3247417B1 (en) |
AU (1) | AU2016209433B2 (en) |
CA (1) | CA2974354C (en) |
DK (1) | DK3247417T3 (en) |
ES (1) | ES2865503T3 (en) |
HU (1) | HUE054393T2 (en) |
LT (1) | LT3247417T (en) |
WO (1) | WO2016118569A1 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018044839A1 (en) * | 2016-08-29 | 2018-03-08 | Hollister Incorporated | Methods of selectively modifying the flexibility of medical tubes |
WO2019092686A1 (en) | 2017-11-13 | 2019-05-16 | Teleflex Life Sciences Unlimited Company | Frictionless catheter |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2509241A (en) * | 1947-05-10 | 1950-05-30 | Ortho Pharma Corp | Applicator |
US2948697A (en) * | 1958-04-23 | 1960-08-09 | Du Pont | Plasticized polyvinyl alcohol composition |
US4346712A (en) | 1979-04-06 | 1982-08-31 | Kuraray Company, Ltd. | Releasable balloon catheter |
US4734941A (en) * | 1987-05-13 | 1988-04-05 | Dewitt Elizabeth M | Flushable urine conducting appliance |
DE3939721C2 (en) * | 1988-12-05 | 2002-08-01 | Nippon Synthetic Chem Ind | Polyvinyl alcohol-starch film |
US5049138A (en) * | 1989-11-13 | 1991-09-17 | Boston Scientific Corporation | Catheter with dissolvable tip |
JPH0564660A (en) * | 1991-05-21 | 1993-03-19 | Sumitomo Bakelite Co Ltd | Medical catheter and making thereof |
US5308342A (en) | 1991-08-07 | 1994-05-03 | Target Therapeutics, Inc. | Variable stiffness catheter |
JP2804200B2 (en) | 1992-03-13 | 1998-09-24 | 株式会社クリニカル・サプライ | Medical device having lubricious surface when wet and method for producing the same |
US5601538A (en) * | 1995-03-07 | 1997-02-11 | Medtronic, Inc. | Flow directed catheter with hydrophilic distal end |
US20020156452A1 (en) * | 1996-02-16 | 2002-10-24 | Pursley Matt D. | Method and apparatus for curving catheter with soft distal end |
US5800412A (en) | 1996-10-10 | 1998-09-01 | Sts Biopolymers, Inc. | Hydrophilic coatings with hydrating agents |
US5938653A (en) | 1997-06-09 | 1999-08-17 | Scimed Life Systems, Inc. | Catheter having controlled flexibility and method of manufacture |
US6184261B1 (en) * | 1998-05-07 | 2001-02-06 | Board Of Regents Of University Of Nebraska | Water-resistant degradable foam and method of making the same |
US7935108B2 (en) | 1999-07-14 | 2011-05-03 | Cardiofocus, Inc. | Deflectable sheath catheters |
US6579277B1 (en) | 1999-09-24 | 2003-06-17 | Omnisonics Medical Technologies, Inc. | Variable stiffness medical device |
ES2222253T3 (en) * | 1999-11-17 | 2005-02-01 | Reckitt Benckiser (Uk) Limited | WATER SOLUBLE CONTAINERS MOLDED BY INJECTION. |
US6544451B1 (en) * | 2000-06-26 | 2003-04-08 | E. I. Du Pont De Nemours And Company | Direct sheet extrusion of solid surface sheet and profiled materials |
EP1228850B1 (en) * | 2001-01-22 | 2010-07-28 | Kuraray Co., Ltd. | Method for producing ethylene-vinyl alcohol copolymer resin composition |
EP1251147B1 (en) * | 2001-04-20 | 2004-09-08 | Kuraray Co., Ltd. | Water-soluble film and package using the same |
US6610025B2 (en) * | 2001-08-06 | 2003-08-26 | The Procter & Gamble Company | Tampon applicator arrangement |
DE10142922A1 (en) * | 2001-09-01 | 2003-03-20 | Kuraray Specialities Europe | Polyvinyl alcohol moldings, processes for their production by means of thermoplastic processes and their use |
WO2003028783A1 (en) | 2001-10-03 | 2003-04-10 | Boston Scientific Limited | Medical device with polymer coated inner lumen |
WO2003076513A1 (en) * | 2002-03-04 | 2003-09-18 | Buckley, Chad | Improved polyvinyl alcohol film and method of producing the same |
WO2003077981A2 (en) * | 2002-03-20 | 2003-09-25 | Manfred Sauer | Catheter |
US20070043333A1 (en) | 2002-10-03 | 2007-02-22 | Scimed Life Systems, Inc. | Method for forming a medical device with a polymer coated inner lumen |
EP1415671A1 (en) | 2002-11-01 | 2004-05-06 | Polyganics B.V. | Biodegradable drains for medical applications |
US20050283111A1 (en) | 2004-06-22 | 2005-12-22 | Dan Maurice | Catheter assembly with degradable material |
WO2006071813A2 (en) | 2004-12-23 | 2006-07-06 | Massachusetts Institute Of Technology | Disposable medical supplies from hydrolytically biodegradable plastics |
GB2422150B (en) | 2005-01-13 | 2009-11-25 | Pvaxx Res & Dev Ltd | PVA-containing compositions |
JP2008539320A (en) * | 2005-04-28 | 2008-11-13 | モノソル エルエルシー | Water-soluble composition and structure, and method for producing and using the same |
WO2006124484A1 (en) * | 2005-05-13 | 2006-11-23 | The Procter & Gamble Company | Functionalized films |
US7998132B2 (en) * | 2005-09-02 | 2011-08-16 | Boston Scientific Scimed, Inc. | Adjustable stiffness catheter |
WO2007062265A2 (en) * | 2005-11-28 | 2007-05-31 | New Ice Limited | Processes for filming biodegradable or compostable containers |
US20070129690A1 (en) | 2005-12-02 | 2007-06-07 | Joel Rosenblatt | Catheter with polymeric coating |
US7745517B2 (en) * | 2006-05-02 | 2010-06-29 | Sekisui Specialty Chemicals America, Llc | Polyvinyl alcohol films with improved resistance to oxidizing chemicals |
KR100718280B1 (en) * | 2006-06-08 | 2007-05-16 | 재단법인서울대학교산학협력재단 | Poly(vinyl chloride) product containing cyclodextrin derivatives with suppression of the migration of plasticizer and manufacturing method thereof |
US8440318B2 (en) * | 2006-07-05 | 2013-05-14 | The Procter & Gamble Company | Water-soluble substrate with resistance to dissolution prior to being immersed in water |
WO2008095327A1 (en) * | 2007-02-08 | 2008-08-14 | Woodwelding Ag | Implant, method of preparing an implant, implantation method, and kit of parts |
CN101396600B (en) * | 2007-09-30 | 2012-11-07 | 江门市宝德利水溶性塑料有限公司 | Water soluble biological degradation type golf balls and preparation method thereof |
KR100847115B1 (en) * | 2007-10-16 | 2008-07-18 | 센트럴메디컬서비스(주) | Double packing materials for infusion solution |
GB0805879D0 (en) * | 2008-04-01 | 2008-05-07 | Reckitt Benckiser Nv | Injection moulded containers |
US8338508B2 (en) * | 2008-05-14 | 2012-12-25 | Kimberly-Clark Worldwide, Inc. | Water-sensitive film containing an olefinic elastomer |
JP5784506B2 (en) | 2009-02-20 | 2015-09-24 | ボストン サイエンティフィック サイムド,インコーポレイテッドBoston Scientific Scimed,Inc. | Manipulable catheter having a transition region with intermediate stiffness |
WO2011031857A2 (en) | 2009-09-09 | 2011-03-17 | Sabin Corporation | Substrate surface modification utilizing a densified fluid and a surface modifier |
DK2301595T3 (en) | 2009-09-23 | 2014-04-07 | Dentsply Ih Ab | Translucent catheter and method for making such a catheter |
JP5596120B2 (en) * | 2010-03-05 | 2014-09-24 | テルモ株式会社 | catheter |
US8440090B2 (en) | 2010-04-29 | 2013-05-14 | Abbott Cardiovascular Systems Inc. | Apparatus and method of making a variable stiffness multilayer catheter tubing |
JP2014509240A (en) * | 2010-10-19 | 2014-04-17 | アイ2アイシー コーポレイション | Manufacturing apparatus and manufacturing method of object having change in particle concentration |
WO2012071105A1 (en) | 2010-11-24 | 2012-05-31 | Cook Medical Technologies Llc | Variable stiffness catheter, intraluminal treatment system, and method |
CA2852224A1 (en) * | 2011-10-14 | 2013-04-18 | Volcano Corporation | Medical tubing and associated devices, systems, and methods |
HUE041859T2 (en) * | 2012-11-14 | 2019-06-28 | Hollister Inc | Disposable catheter with selectively degradable inner core |
US9320656B2 (en) * | 2013-11-27 | 2016-04-26 | Kimberly-Clark Worldwide, Inc. | Water-dispersible thermoplastic injection molded composition |
LT3079751T (en) * | 2013-12-12 | 2019-07-25 | Hollister Incorporated | Water disintegrable flushable catheter with a hydrophilic coating |
US9265512B2 (en) * | 2013-12-23 | 2016-02-23 | Silk Road Medical, Inc. | Transcarotid neurovascular catheter |
-
2016
- 2016-01-20 HU HUE16702644A patent/HUE054393T2/en unknown
- 2016-01-20 ES ES16702644T patent/ES2865503T3/en active Active
- 2016-01-20 EP EP16702644.2A patent/EP3247417B1/en active Active
- 2016-01-20 LT LTEP16702644.2T patent/LT3247417T/en unknown
- 2016-01-20 CA CA2974354A patent/CA2974354C/en active Active
- 2016-01-20 US US15/543,839 patent/US10946120B2/en active Active
- 2016-01-20 DK DK16702644.2T patent/DK3247417T3/en active
- 2016-01-20 AU AU2016209433A patent/AU2016209433B2/en active Active
- 2016-01-20 WO PCT/US2016/014034 patent/WO2016118569A1/en active Application Filing
Non-Patent Citations (1)
Title |
---|
None * |
Also Published As
Publication number | Publication date |
---|---|
WO2016118569A1 (en) | 2016-07-28 |
ES2865503T3 (en) | 2021-10-15 |
ES2865503T8 (en) | 2022-02-01 |
EP3247417A1 (en) | 2017-11-29 |
CA2974354A1 (en) | 2016-07-28 |
DK3247417T3 (en) | 2021-04-26 |
AU2016209433A1 (en) | 2017-08-03 |
US10946120B2 (en) | 2021-03-16 |
CA2974354C (en) | 2021-11-16 |
LT3247417T (en) | 2021-04-12 |
HUE054393T2 (en) | 2021-09-28 |
AU2016209433B2 (en) | 2020-04-16 |
US20170368232A1 (en) | 2017-12-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0439908B1 (en) | Lubricous coatings, medical articles containing same and method for their preparation | |
EP0496305B1 (en) | Method for applying a lubricious coating to an article | |
KR102569369B1 (en) | Urethral catheter with soft tip | |
AU2006270542B2 (en) | Urinary catheter | |
US5484565A (en) | Method for making a medical catheter | |
EP0404517B1 (en) | Thermoplastic elastomeric hydrophilic polyetherurethane expandable catheter | |
EP3065793B1 (en) | Oleophilic lubricated catheters | |
US5993436A (en) | Indwelling catheter with improved kinking resistance | |
EP2879729B1 (en) | Self-lubricated catheters | |
EP1951330B1 (en) | Lubricious compound and medical device made of the same | |
JPH0553508B2 (en) | ||
EP3079751B1 (en) | Water disintegrable flushable catheter with a hydrophilic coating | |
EP3693032B1 (en) | Hydrophilic medical device | |
EP2745868A1 (en) | Medical device and method of producing thereof having a tubular substrate and at least partly surface treated access openings | |
EP3247417B1 (en) | Lubricious urinary catheters having varying flexibility | |
JPH1024100A (en) | Manufacture of medical article | |
CA2070252C (en) | A polymeric article such as a medical catheter and method for making the same | |
IE902200A1 (en) | Thermoplastic elastomeric hydrophilic polyetherurethane¹expandable catheter |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
17P | Request for examination filed |
Effective date: 20170814 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
AX | Request for extension of the european patent |
Extension state: BA ME |
|
DAV | Request for validation of the european patent (deleted) | ||
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: EXAMINATION IS IN PROGRESS |
|
17Q | First examination report despatched |
Effective date: 20191128 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
INTG | Intention to grant announced |
Effective date: 20201029 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: GRANT OF PATENT IS INTENDED |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE PATENT HAS BEEN GRANTED |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP Ref country code: AT Ref legal event code: REF Ref document number: 1369091 Country of ref document: AT Kind code of ref document: T Effective date: 20210315 |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R096 Ref document number: 602016053958 Country of ref document: DE |
|
REG | Reference to a national code |
Ref country code: NL Ref legal event code: FP |
|
REG | Reference to a national code |
Ref country code: DK Ref legal event code: T3 Effective date: 20210422 |
|
REG | Reference to a national code |
Ref country code: SE Ref legal event code: TRGR |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210610 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210610 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210611 |
|
REG | Reference to a national code |
Ref country code: AT Ref legal event code: MK05 Ref document number: 1369091 Country of ref document: AT Kind code of ref document: T Effective date: 20210310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 |
|
REG | Reference to a national code |
Ref country code: HU Ref legal event code: AG4A Ref document number: E054393 Country of ref document: HU |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2865503 Country of ref document: ES Kind code of ref document: T3 Effective date: 20211015 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210712 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210710 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R097 Ref document number: 602016053958 Country of ref document: DE |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 |
|
26N | No opposition filed |
Effective date: 20211213 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210710 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
REG | Reference to a national code |
Ref country code: BE Ref legal event code: MM Effective date: 20220131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220120 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220131 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220131 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20220131 |
|
P01 | Opt-out of the competence of the unified patent court (upc) registered |
Effective date: 20230520 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: NL Payment date: 20240126 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: LT Payment date: 20240103 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20240201 Year of fee payment: 9 Ref country code: IE Payment date: 20240129 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: HU Payment date: 20240111 Year of fee payment: 9 Ref country code: DE Payment date: 20240129 Year of fee payment: 9 Ref country code: GB Payment date: 20240129 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: SE Payment date: 20240127 Year of fee payment: 9 Ref country code: IT Payment date: 20240122 Year of fee payment: 9 Ref country code: FR Payment date: 20240125 Year of fee payment: 9 Ref country code: DK Payment date: 20240125 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20210310 |